Der Einsatz von Tyrosinkinase-Inhibitoren bei aktivierenden EGFR-Mutationen in der Erstlinientherapie beim fortgeschrittenen nicht-kleinzelligen Lungenkarzinom (NSCLC) – aktueller Stand und Entwicklungen

R. Wiewrodt; M. Serke; C. Grohé; W. Brückl

doi:10.1055/s-0033-1356039

TumorDiagnostik & Therapie, Inhaltsverzeichnis

TumorDiagnostik & Therapie 2013; 34(8): 469-476
DOI: 10.1055/s-0033-1356039

Thieme Onkologie aktuell

Der Einsatz von Tyrosinkinase-Inhibitoren bei aktivierenden EGFR-Mutationen in der Erstlinientherapie beim fortgeschrittenen nicht-kleinzelligen Lungenkarzinom (NSCLC) – aktueller Stand und Entwicklungen

Employing Tyrosine Kinase Inhibitors in the First Line Treatment of EGFR-Positive Metastatic NSCLC – State of the Art and Recent Developments

R. Wiewrodt

¹Klinik und Poliklinik für Innere Medizin A (Hämatologie, Onkologie und Pneumologie) Universitätsklinikum Münster

,

M. Serke

²Lungenklinik Hemer

,

C. Grohé

³Evangelische Lungenklinik Berlin

,

W. Brückl

⁴Med. Klinik 3, Klinikum Nürnberg

› Institutsangaben

Abstract

Zusammenfassung

In diesem Artikel präsentieren wir einen Überblick über die aktuellen Entwicklungen im Bereich der EGFR-TKI beim Lungenkarzinom. Neben den etablierten Substanzen Erlotinib und Gefitinib liegt der Fokus auf klinischen Daten zu den irreversiblen TKI der zweiten Generation wie Afatinib, Dacomitinib, Neratinib, Pelitinib und Canertinib, die nicht nur den EGF-Rezeptor blockieren, sondern sich durch ein breiteres Wirkspektrum auszeichnen. Auch Anwendungen von aus anderen Indikationen bekannten und dort zugelassenen TKI wie Lapatinib und Vandetanib bei NSCLC werden beleuchtet. Ein wichtiger Aspekt in der Behandlung mit TKI ist neben den reinen Überlebensdaten der Erhalt der Lebensqualität der Patienten, der bei der Wahl der Therapie mit berücksichtigt werden sollte.

Abstract

In this review article we present an overview of recent developments in EGFR TKIs in lung cancer therapy. Besides the approved drugs erlotinib and gefitinib, clinical data on second-generation irreversible TKIs including afatinib, dacomitinib, neratinib, pelitinib, and canertinib are mentioned; these drugs not only inactivate EGFR but show a broader range of activity. We also report on NSCLC data of TKI that are known and approved in other indications, such as lapatinib and vandetanib. We stress the importance of quality of life in the treatment of patients with TKIs, an important aspect of the treatment that should also be considered in the selection of the appropriate NSCLC therapy in advanced stages.

Volltext

Referenzen

Literatur
1 Statistisches Bundesamt. Pressemitteilung Nr. 042. 04.02.2013 Im Internet: https://www.destatis.de/DE/PresseService/Presse/Pressemitteilungen/2013/02/PD13_042_232.html Stand: 21.05.2013
2 Goeckenjan G, Sitter H, Thomas M et al. Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms. Interdisziplinäre S3-Leitlinie der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin und der Deutschen Krebsgesellschaft. Pneumologie 2010; 64: e1-e164
3 National Institute for Clinical Excellence (NICE), National Collaborating Centre for Acute Care. Diagnosis and treatment of lung cancer. London: 2005 Im Internet: www.nice.org.uk/nicemedia/pdf/cg024fullguideline Stand: 21.05.2013
4 lberg AJ, Ford JG, Sarnet JM. Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007; 132: 29-55
5 Liu S, Wang D, Chen B et al. The safety and efficacy of EGFR TKIs monotherapy versus single-agent chemotherapy using third-generation cytotoxics as the first-line treatment for patients with advanced non-small cell lung cancer and poor performance status. Lung Cancer 2011; 73: 203-210
6 Schuette W, Eberhardt WE, von der Schulenburg JM et al. EGFR mutation analysis from REASON: A registry for the epidemiologic and scientific evaluation of EGFR mutation status in newly diagnosed NSCLC patients stage IIIB/IV. J Clin Oncol 2012; 30 (Suppl. abstr e18016)
7 Zhang Y, Sun Y, Pan Y et al. Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis. Clin Cancer Res 2012; 18: 1947-1953
8 Mok T, Wu YL, Thongprasert S et al. Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947-957
9 Fukuoka M, Wu YL, Thongprasert S et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 2011; 29: 2866-2874
10 Mitsudomi T, Morita S, Yatabe Y et al. West Japan Oncology Group. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010; 11: 121-128
11 Maemondo M, Inoue A, Kobayashi K et al. North-East Japan Study Group. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010; 362: 2380-2388
12 Rosell R, Carcereny E, Gervais R et al. Spanish Lung Cancer Group (in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica). Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012; 13: 239-246
13 Zhou C, Wu YL, Chen G et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011; 12: 735-742
14 Jackman D, Pao W, Riely GJ et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol 2010; 28: 357-360
15 Ioannou N, Dalgleish AG, Seddon AM et al. Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells. Br J Cancer 2011; 105: 1554-1562
16 Khelwatty SA, Essapen S, Seddon AM et al. Growth response of human colorectal tumour cell lines to treatment with afatinib (BIBW2992), an irreversible erbB family blocker, and its association with expression of HER family members. Int J Oncol 2011; 39: 483-491
17 Yang JC, Shih JY, Su WC et al. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncol 2012; 13: 539-548
18 Miller VA, Hirsh V, Cadranel J et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol 2012; 13: 528-538
19 Yang JCH, Schuler M, Yamamoto N et al. LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. J Clin Oncol 2012; 30 (Suppl. abstr LBA7500)
20 Engelman JA, Zejnullahu K, Gale CM et al. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res 2007; 67: 11924-11932
21 Park K, Heo DS, Cho B et al. PF-00299804 (PF299) in Asian patients (pts) with non-small cell lung cancer (NSCLC) refractory to chemotherapy (CT) and erlotinib (E) or gefitinib (G): A phase (P) I/II trial [abstract]. J Clin Oncol 2010; s28: 7599
22 Ramalingam SS, Blackhall F, Krzakowski M et al. Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol 2012; 30: 3337-3344
23 Kris M, Goldberg Z, Janne PA et al. Dacomitinib (PF-00299804), an irreversible pan-HER tyrosine kinase inhibitor (TKI), for first-line treatment of EGFR-mutant or HER2-mutant or – amplified lung cancers. Ann Oncol 2012; 23 (Suppl. 09) 401
24 Rabindran SK, Discafani CM, Rosfjord EC et al. Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res 2004; 64: 3958-3965
25 Wong KK, Fracasso PM, Bukowski RM et al. A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors. Clin Cancer Res 2009; 15: 2552-2558
26 Sequist LV, Besse B, Lynch TJ et al. Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer. J Clin Oncol 2010; 28: 3076-3083
27 Nunes M, Shi C, Greenberger LM. Phosphorylation of extracellular signal-regulated kinase 1 and 2, protein kinase B, and signal transducer and activator of transcription 3 are differently inhibited by an epidermal growth factor receptor inhibitor, EKB-569, in tumor cells and normal human keratinocytes. Mol Cancer Ther 2004; 3: 21-27
28 Erlichman C, Hidalgo M, Boni JP et al. Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors. J Clin Oncol 2006; 24: 2252-2260
29 Yoshimura N, Kudoh S, Kimura T et al. EKB-569, a new irreversible epidermal growth factor receptor tyrosine kinase inhibitor, with clinical activity in patients with non-small cell lung cancer with acquired resistance to gefitinib. Lung Cancer 2006; 51: 363-368
30 Allen LF, Eiseman IA, Fry DW et al. CI-1033, an irreversible pan-erbB receptor inhibitor and its potential application for the treatment of breast cancer. Semin Oncol 2003; 30 (5 Suppl 16): 65-78
31 Chiappori AA, Ellis PM, Hamm JT et al. A phase I evaluation of oral CI-1033 in combination with paclitaxel and carboplatin as first-line chemotherapy in patients with advanced non-small cell lung cancer. J Thorac Oncol 2006; 1: 1010-1019
32 Jänne PA, von Pawel J, Cohen RB et al. Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non small-cell lung cancer. J Clin Oncol 2007; 25: 3936-3944
33 Ross HJ, Blumenschein Jr GR, Aisner J et al. Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer. Clin Cancer Res 2010; 16: 1938-1949
34 Wedge SR, Ogilvie DJ, Dukes M et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002; 62: 4645-4655
35 Heymach JV, Paz-Ares L, De Braud F et al. Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 2008; 26: 5407-5415
36 Heymach JV, Johnson BE, Prager D et al. Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. J Clin Oncol 2007; 25: 4270-4277
37 Herbst RS, Sun Y, Eberhardt WE et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol 2010; 11: 619-626
38 Lee JS, Hirsh V, Park K et al. Vandetanib versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR). J Clin Oncol 2012; 30: 1114-1121
39 Natale RB, Thongprasert S, Greco FA et al. Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 2011; 29: 1059-1066
40 de Boer RH, Arrieta Ó, Yang CH et al. Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial. J Clin Oncol 2011; 29: 1067-1074
41 Schiller JH, Harrington D, Belani CP et al. Comparison of four chemotherapy regimens for advanced non–small-cell lung cancer. N Engl J Med 2002; 346: 92-98
42 Rosell R, Moran T, Queralt C et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009; 361: 958-967
43 Mok T, Wu YL, Thongprasert S et al. Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma. N Engl J Med 2009; 361: 947-957
44 Thongprasert S, Duffield E, Saijo N et al. Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS). J Thorac Oncol 2011; 6: 1872-1880
45 Oizumi S, Kobayashi K, Inoue A et al. Quality of life with gefitinib in patients with EGFR-mutated non-small cell lung cancer: quality of life analysis of North East Japan Study Group 002 Trial. Oncologist 2012; 17: 863-870
46 de Lima Lopes Jr G, Segel JE, Tan DS. et al Cost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung. Cancer 2012; 118: 1032-1039
47 von Pawel J. Brauchen wir beim metastasierten Adenokarzinom der Lunge immer eine EGFR-Mutationsanalyse vor der palliativen Firstline-Therapie? Contra. Dtsch Med Wochenschr 2012; 137: 593
48 Brückl W. Brauchen wir beim metastasierten Adenokarzinom der Lunge immer eine EGFR-Mutationsanalyse vor der palliativen Firstline-Therapie? Pro. Dtsch Med Wochenschr 2012; 137: 592
49 Ranson M, Pao W, Kim DW et al. LATE BREAKING ABSTRACT: Preliminary results from a Phase I study with AZD9291: An irreversible inhibitor of epidermal growth factor receptor (EGFR) activating and resistance mutations in non-small-cell lung cancer (NSCLC). EJC 2013; 47 Supplement 2
50 Soria J-C, Sequist LV, Gadgeel S et al. Evaluation of CO-1686, an Irreversible, Highly, Selective Tyrosine Kinase Inhibitor of Mutations of EGFR (Activating and T790M). JTO 2013; 8 Suppl. 2